Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

ITK inhibitors may effectively treat alopecia areata.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

Certain tyrosine kinases may regulate hair growth and could help develop hair loss treatments.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This review reports that Janus kinase inhibitors and regenerative therapies, such as exosomes and platelet-rich plasma, significantly improve scalp hair regrowth in moderate-to-severe alopecia areata, though challenges like high relapse rates and socioeconomic barriers remain, underscoring the need for personalized treatment protocols.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This review highlights that T cells are crucial in regulating hair follicle regeneration and their disruption can lead to alopecia, providing insights into hair disorders related to T cell immune balance and hair follicle regeneration.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This review highlights emerging evidence that chemotherapy-induced alopecia may be driven by immune mechanisms similar to alopecia areata, involving hair follicle immune privilege collapse, and evaluates Janus kinase inhibitors as potential treatments, while cautioning about their immunosuppressive risks in cancer patients.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.

This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This study demonstrates that canonical Wnt signaling is crucial for maintaining thymic epithelial microenvironments in postnatal thymus, possibly by affecting TEC progenitor cells.

This study reported that new drugs, despite lower specificity compared to certain immunobiological therapies, are effective across various challenging dermatological diseases, such as psoriasis, psoriatic arthritis, atopic dermatitis, alopecia areata, and vitiligo.

This narrative review proposes the concept of "repigmentation competence" for vitiligo lesions, suggesting that therapy responses are influenced by lesion-specific biological factors related to immune, regenerative, regulatory, and microenvironmental processes, and highlights the emerging role of combination therapies targeting these pathways.